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This issue of Therapeutics and Clinical Risk Management contains four comprehen-
sive review articles which focus on disorders of the skin. Psoriasis vulgaris represents 
the most common form of psoriasis. Symptoms include red, raised, scaly lesions that 
usually occur symmetrically in areas subjected to trauma such as the elbows and 
knees. Although not considered life-threatening, this is an unpleasant, distressing 
condition that impacts on quality of life and patient well-being. The chronic nature 
of the condition requires long-term therapy thereby raising compliance and safety 
issues. The pathogenesis of psoriasis vulgaris is not well understood but is thought 
to involve a complex interaction between genetic and environmental factors that 
impact on innate and acquired immunity. This results in an inﬂ  ammatory cutaneous 
response in which T cells, dendritic cells and pro-inﬂ  ammatory chemokines play 
particularly important roles. Most treatments are topical with corticosteroids and 
vitamin D3 analogues being the treatment of choice. Efstratios Vakirlis and col-
leagues (2008) provide a comprehensive review of the efﬁ  cacy of treating psoriasis 
vulgaris with a topical treatment that combines calcipotriol, a vitamin D analog with 
the corticosteroid betamethasone dipropionate. The authors review the mechanisms 
by which the two compound ointments (Dovobet®, Daivobet®, Taclonex®) attenuate 
the inﬂ  ammatory cascade that results in the symptoms of psoriasis. The combination 
of the two therapies has a positive additive effect with lesions clearing more quickly 
compared with separate application of corticosteroids and calcipotriol. The authors also 
highlight the technical demands of creating the dual formulation due to the tendency 
of calcipotriol and topical steroids to inactivate each other when mixed in a single 
formulation. The available randomized clinical trials with the combination medication 
are comprehensively reviewed together with safety and tolerability for the treatment. 
It appears that the requirement for a once daily application and a rapid onset of action 
improves patient compliance. Overall the authors’ opinion is that dual formulation of 
calcipotriol and topical steroids is a safe and effective treatment for psoriasis vulgaris 
either as initial therapy or as adjunct therapy in patients who also require systemic 
treatment or phototherapy. 
The second review of treatment of dermatological disorders is focused on the im-
mune-response modifying agent imiquimod (Lacarrubba et al 2008). This is a synthetic 
imidazoquinoline amine that enhances, through cytokine induction, both the innate and 
acquired immune pathways, resulting in antiviral and antitumor effects. Imiquimod 
stimulates the immune system in several ways but the main pathway appears to be 
through the toll-like receptor (TLR)-7, activation of which induces release of pro-
inﬂ  ammatory cytokines from Langerhans cells, monocytes/macrophages and dendritic 
cells. This in turn results in T cell activation and subsequent killing of virus-infected 
cells and tumors. The authors review the randomized clinical trials with imiquimod 
that show it to be an effective treatment for genital and perianal warts, actinic kerato-
ses, basal cell carcinomas, Bowen’s disease, and molluscum contagiosum. However, 
imiquimod treatment is not without side-effects with some patients experiencing mild 
to severe local skin reactions that may extend beyond the treatment area.
The current issue also contains two reviews on the treatment of complicated skin 
and tissue infections. These sites are particularly vulnerable to bacterial infections, 
often after surgical procedures, and many of these are caused by antibiotic-resistant 
strains making treatment difﬁ  cult. Effective management of complicated skin and 
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tissue infections requires timely instigation of appropriate 
antimicrobial therapy. There is particular concern over the 
extent of infections caused by resistant strains of Staphy-
lococcus aureus, one of the most common and virulent 
Gram-positive bacteria encountered clinically. S. aureus is 
responsible for both Methicillin-resistant S. aureus (MRSA) 
and the more serious hospital-acquired MRSA that exhibits 
multidrug resistance, including resistance to all the lactam 
antibiotics, penems, and carbapenems. The review by Lala 
Dunbar and colleagues (2008) deﬁ  nes the role of Telavancin, 
a once-daily intravenous lipoglycopeptide antibiotic that 
exhibits bactericidal activity via a dual mechanism cur-
rently under regulatory review in both the United States 
and Europe for the treatment of complicated skin and tissue 
infections. The authors present ﬁ  ndings from phase II and III 
multinational, randomized, double-blinded studies that show 
Telavancin to be an effective therapy. The authors conclude 
that current evidence on telavancin supports its safety and 
effectiveness in the treatment of complicated skin infec-
tions and following regulatory approval it should provide 
an important new option in the treatment of serious infec-
tions caused by resistant Gram-positive bacteria. Another 
potentially important novel treatment for complicated skin 
and tissue infections is dalbavancin, a parenterally admin-
istered semi-synthetic lipoglycopeptide antibiotic similar 
to the naturally produced glycopeptides vancomycin and 
teicoplanin. The review by Bennet and colleagues (2008) 
in the current issue provides comprehensive information on 
the phacokinetics, pharmacodynamics, and antimicrobial 
activity of dalbavancin together with available evidence of 
efﬁ  cacy from phase II and III clinical trials in patients with 
complicated skin and tissue infections. Like telavancin, 
dalbavancin is awaiting regulatory approval but both should 
prove to be useful additions to the treatment of infections 
caused by multiple drug-resistant bacterial strains.
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